An AI-designed drug for chronic lung disease dramatically reversed the markers of biological aging in its first clinical trials. In a clinical trial published in Nature Biotechnology, scientists evaluating the drug rentosertib — developed by generative artificial intelligence for idiopathic pulmonary fibrosis (IPF) — discovered it also significantly lowered biological age. Evaluating blood-protein samples from 42 trial participants across six independent 'proteomic aging clocks,' the researchers observed a consistent shift toward younger biological profiles, with some models estimating a decline in biological age of up to several years. In contrast, patients receiving a placebo showed virtually no change or even slight increases in their biological aging markers over the 12-week study. While these results are highly promising, researchers caution that they are still preliminary. Because idiopathic pulmonary fibrosis is an age-related illness characterized by severe tissue damage and inflammation, it remains unclear whether rentosertib directly targets the aging process itself or if treating the underlying lung disease simply altered the specific blood proteins tracked by the aging clocks. Furthermore, because the trial was small and lasted only three months, scientists emphasize that larger, longer-term clinical studies are required to verify if these biological age reversals translate to lasting, tangible health benefits for patients. source: Insilico Medicine. (2026). Integration of proteomic aging clocks in a phase 2a clinical trial of rentosertib. Nature Biotechnology.

In 12 weeks, we built a research facility that is run entirely by AI. AI designs, executes, and observes experiments end-to-end across biology, chemistry, and materials science. We’re introducing SciUniverse: a benchmark that measures AI’s ability to do real-world scientific research.

NEW - Anthropic CEO Dario Amodei says their Claude AI model has led to the discovery of a “new molecular machine” capable of gene editing

📈 IT services will more than double: from $1.61T in 2025 to $3.48T by 2034 (8.9% CAGR), driven by digital transformation, cloud, AI and legacy modernization. Is your roadmap ready? buff.ly/THXDZn6 #DigitalTransformation #ITServices #Cloud #CIO #AI #Modernization #IT

New @aiunderwriting report with coverage in the @FT! Insurance is an underrated lever for AI governance. It creates a market demand for a lot of the things we need: > Incident data collection and analysis > Standard setting > Audits and risk evaluation > Monitoring > Incident response services > Catastrophe modeling

The real “aha” for me: We are moving from prompting… to managing outcomes. Instead of crafting the perfect input, you: → Define the objective → Review the execution plan → Approve or refine That’s not a better chatbot. That’s a digital coworker. And it changes how leaders design workflows.

CEO of America’s largest public hospital system says he’s ready to replace radiologists with #AI radiologybusiness.com/topics… @RadiologyBiz Dario Amodei, CEO of Anthropic, in a podcast interview, falsely stated that AI has taken over the radiologist specialty’s core function, allowing doctors to focus more on the human side of the job. Radiologists roundly criticized Amodei’s remarks. Mohammed Suhail, MD, a San Diego-based rad with North Coast Imaging, said: “Undeniable proof that confidently uninformed hospital administrators are a danger to patients: easily duped by AI companies that are nowhere near capable of providing patient care,” Suhail told Radiology Business. “Any attempt to implement AI-only reads would immediately result in patient harm and death, and only someone with zero understanding of radiology would say something so naive. But in some sense, they’re correct: Hospitals are happy to cut costs even if it means patient harm, as long as it’s legal.” Now, Mitchell H. Katz, MD, president & CEO of NYC Health + Hospitals, said: "I'm prepared to start replacing radiologists with artificial intelligence, once the regulatory landscape catches up." My PoV here: Instead of trying to cut costs by replacing humans with AI in the healthcare system, it would be far wiser to first effectively regulate the U.S. healthcare system to cut costs in this healthcare system which is a ruinous maze with mediocre performance—a system where medical care is controlled by large private corporations, a costly system for patients, and where yields results are far inferior to those of comparable countries in terms of public health. And as always, the poorest are the first to suffer here. -- Cc @jblefevre60 @Ym78200 @ahier @aure79lien @DeepLearn007 @EvanKirstel @gvalan @AkwyZ @nincoroby @kalydeoo @IanLJones98 @BetaMoroney @enilev @mvollmer1 @mikeflache @Khulood_Almani @Nicochan33 @HaroldSinnott @RLDI_Lamy @CathCervoni @LaurentAlaus @CurieuxExplorer @FrRonconi @Fabriziobustama @chidambara09 @CHRISTINESOTO12 @dinisguarda